Latest News and Press Releases

Company to review BXCL502 and other potential emerging pipeline candidates   Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and BXCL502 as a potential treatment for chronic...

Vincent J. O’Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer   Rajiv Patni, M.D., appointed Strategic Clinical Advisor to CEO and Board of...

Company to review BXCL502 and other potential emerging pipeline candidates   Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and BXCL502 as a potential treatment Dr. Sandra...

Company plans to conduct Phase 3 trial of BXCL501 in the at-home setting for TRANQUILITY program to support potential sNDA for acute treatment of agitation associated with dementia due to probable...

Median overall survival of 15.5 months with BXCL701 + KEYTRUDA® (pembrolizumab), compared to 9.6 months with checkpoint inhibitor monotherapy in late-line refractory patients in separate Phase 2...

Columbia University-led trial expected to add fourth site to target completion of 4-arm, 160-patient trial in 2024 Fentanyl adulterated or associated with xylazine (FAAX) designated an emerging...

NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in...

Standardizes and improves product reimbursement process New HCPCS Level II code J1105 to be effective January 1, 2024 NEW HAVEN, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc....

No evidence of misconduct or fraud found beyond instance previously reported1 No findings identified that impact data integrity Company believes audit findings support reliability of positive...

Median overall survival of 13.6 months with BXCL701 + KEYTRUDA® (pembrolizumab), compared to 7.6 months with checkpoint inhibitor monotherapy (CPI) in late-line refractory patients in separate, Phase...